Unblinded by the light: amyloid‐related imaging abnormalities in Alzheimer’s clinical trials

descriptionPublicationkeyboard_double_arrow_right Article 09 Sep 2020 Australia English Publisher:WileyJournal:European Journal of Neurology, volume 28 (issn: 1351-5101, eissn: 1468-1331,

Copyright policy )

Authors: A. Gleason; S. Ayton; A. I. Bush;

doi: 10.1111/ene.14484

handle: 11343/276251

Unblinded by the light: amyloid‐related imaging abnormalities in Alzheimer’s clinical trials

- Summary
- Metrics

Abstract

A disease modifying therapy for Alzheimer's disease is one of the highest priorities in medicine. Dozens of amyloid-modifying trials have failed to meet primary endpoints. Aducanumab, a monoclonal anti-amyloid antibody, lowers plaque burden. Early findings suggested a slowing of cognitive deterioration(1). However, phase 3 trials of aducanumab were ceased in March 2019 based on a futility analysis.

Country

Australia

Related Organizations

University of Melbourne
Australia
Botany Foundation
Australia
Florey Institute of Neuroscience and Mental Health
Australia

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	19
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%